➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Harvard Business School
Boehringer Ingelheim
McKinsey
Baxter

Last Updated: January 24, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,132,239

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,132,239 protect, and when does it expire?

Patent 9,132,239 protects OZEMPIC and SAXENDA and is included in two NDAs.

Protection for SAXENDA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 9,132,239
Title:Dial-down mechanism for wind-up pen
Abstract: The present invention relates to a dial-down mechanism for an injection device comprising a torsion spring for assisting injection of a dose of medicament from the injection device, the dial-down mechanism comprising a ratchet arm (21) engaging a ring element (10) and a reset element (30) which acts on a knob located on the periphery of the ratchet arm (21) to move the ratchet arm (21) out of engagement with the ring element (10) in order to allow the set dose to be reduced.
Inventor(s): Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsv.ae butted.rd, DK), Radmer; Bo (Hillerod, DK), Enggaard; Christian Peter (Vejby, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:13/124,995
Patent Claim Types:
see list of patent claims
Use; Device;

Recent additions to Drugs Protected by US Patent 9,132,239

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Novo OZEMPIC semaglutide SOLUTION 209637 Dec 5, 2017 RX Yes   Start Trial Y   Start Trial
Novo OZEMPIC semaglutide SOLUTION 209637 Apr 9, 2019 RX Yes   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 9,132,239

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novo OZEMPIC semaglutide SOLUTION;SUBCUTANEOUS 209637-001 Dec 5, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Novo SAXENDA liraglutide recombinant SOLUTION;SUBCUTANEOUS 206321-001 Dec 23, 2014 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,132,239

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08167547Oct 24, 2008
PCT Information
PCT FiledOctober 21, 2009PCT Application Number:PCT/EP2009/063801
PCT Publication Date:April 29, 2010PCT Publication Number: WO2010/046394

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
Express Scripts
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.